WO1998016497A1 - Nouveaux composes de diamide et medicaments les contenant - Google Patents
Nouveaux composes de diamide et medicaments les contenant Download PDFInfo
- Publication number
- WO1998016497A1 WO1998016497A1 PCT/JP1997/003603 JP9703603W WO9816497A1 WO 1998016497 A1 WO1998016497 A1 WO 1998016497A1 JP 9703603 W JP9703603 W JP 9703603W WO 9816497 A1 WO9816497 A1 WO 9816497A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- trimethoxyphenyl
- bis
- mmo
- compound
- Prior art date
Links
- 239000003814 drug Substances 0.000 title claims abstract description 23
- 229940079593 drug Drugs 0.000 title abstract description 6
- 150000001470 diamides Chemical class 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 83
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 20
- 125000002947 alkylene group Chemical group 0.000 claims abstract description 15
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 14
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 13
- 230000016784 immunoglobulin production Effects 0.000 claims abstract description 9
- 125000001624 naphthyl group Chemical group 0.000 claims abstract description 6
- 125000005046 dihydronaphthyl group Chemical group 0.000 claims abstract description 5
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 claims abstract description 5
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 claims abstract description 5
- 125000004076 pyridyl group Chemical group 0.000 claims abstract description 5
- 125000005493 quinolyl group Chemical group 0.000 claims abstract description 5
- 125000001041 indolyl group Chemical group 0.000 claims abstract description 4
- 125000005956 isoquinolyl group Chemical group 0.000 claims abstract description 4
- -1 acrylyl group Chemical group 0.000 claims description 72
- UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 29
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical class C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 25
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 24
- 125000001424 substituent group Chemical group 0.000 claims description 19
- 125000004432 carbon atom Chemical group C* 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 18
- 150000003839 salts Chemical class 0.000 claims description 18
- 125000003545 alkoxy group Chemical group 0.000 claims description 16
- 230000000172 allergic effect Effects 0.000 claims description 13
- 208000010668 atopic eczema Diseases 0.000 claims description 13
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Chemical class COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 12
- 125000005843 halogen group Chemical group 0.000 claims description 11
- 239000012453 solvate Substances 0.000 claims description 11
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 10
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 8
- 150000001491 aromatic compounds Chemical class 0.000 claims description 8
- 208000026278 immune system disease Diseases 0.000 claims description 8
- 125000003282 alkyl amino group Chemical group 0.000 claims description 7
- 125000003277 amino group Chemical group 0.000 claims description 7
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 7
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 6
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical class C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 claims description 6
- 208000006673 asthma Diseases 0.000 claims description 5
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 5
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 claims description 5
- 150000002391 heterocyclic compounds Chemical class 0.000 claims description 5
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 5
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 claims description 5
- 125000001302 tertiary amino group Chemical group 0.000 claims description 5
- 206010012442 Dermatitis contact Diseases 0.000 claims description 4
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 4
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 4
- 206010039085 Rhinitis allergic Diseases 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 4
- 125000004414 alkyl thio group Chemical group 0.000 claims description 4
- 201000010105 allergic rhinitis Diseases 0.000 claims description 4
- 125000003118 aryl group Chemical group 0.000 claims description 4
- 208000010247 contact dermatitis Diseases 0.000 claims description 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 4
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims description 4
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 claims description 4
- 125000003258 trimethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])[*:1] 0.000 claims description 4
- 125000003762 3,4-dimethoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 claims description 3
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Chemical class C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 claims description 3
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical class C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims description 3
- 201000010099 disease Diseases 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 125000001841 imino group Chemical group [H]N=* 0.000 claims description 3
- 239000003112 inhibitor Substances 0.000 claims description 3
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 229910052717 sulfur Inorganic materials 0.000 claims description 2
- 125000004434 sulfur atom Chemical group 0.000 claims description 2
- 206010012438 Dermatitis atopic Diseases 0.000 claims 2
- 201000008937 atopic dermatitis Diseases 0.000 claims 2
- 125000002993 cycloalkylene group Chemical group 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 abstract description 8
- 239000000043 antiallergic agent Substances 0.000 abstract description 3
- 239000001257 hydrogen Substances 0.000 abstract description 3
- 229910052739 hydrogen Inorganic materials 0.000 abstract description 3
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 description 100
- 125000005809 3,4,5-trimethoxyphenyl group Chemical group [H]C1=C(OC([H])([H])[H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 description 73
- 239000000843 powder Substances 0.000 description 61
- 239000002253 acid Substances 0.000 description 50
- 239000013078 crystal Substances 0.000 description 48
- 239000000243 solution Substances 0.000 description 33
- 239000000203 mixture Substances 0.000 description 31
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 30
- 238000002844 melting Methods 0.000 description 29
- 230000008018 melting Effects 0.000 description 29
- 238000004519 manufacturing process Methods 0.000 description 25
- 238000002360 preparation method Methods 0.000 description 18
- 239000011541 reaction mixture Substances 0.000 description 17
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 13
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 12
- NFDFQCUYFHCNBW-SCGPFSFSSA-N dienestrol Chemical compound C=1C=C(O)C=CC=1\C(=C/C)\C(=C\C)\C1=CC=C(O)C=C1 NFDFQCUYFHCNBW-SCGPFSFSSA-N 0.000 description 12
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 12
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 11
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 10
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 10
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
- OXXAEGVEBNPTFY-UHFFFAOYSA-N 3-(3,4,5-trimethoxyphenyl)benzoic acid Chemical compound COC1=C(OC)C(OC)=CC(C=2C=C(C=CC=2)C(O)=O)=C1 OXXAEGVEBNPTFY-UHFFFAOYSA-N 0.000 description 9
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 239000010779 crude oil Substances 0.000 description 9
- 150000004985 diamines Chemical class 0.000 description 9
- 150000002148 esters Chemical class 0.000 description 9
- 239000012044 organic layer Substances 0.000 description 9
- 238000010898 silica gel chromatography Methods 0.000 description 9
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 8
- 238000001816 cooling Methods 0.000 description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical class CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 7
- 150000001408 amides Chemical class 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- PSLIMVZEAPALCD-UHFFFAOYSA-N ethanol;ethoxyethane Chemical compound CCO.CCOCC PSLIMVZEAPALCD-UHFFFAOYSA-N 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- XFNJVJPLKCPIBV-UHFFFAOYSA-N trimethylenediamine Chemical compound NCCCN XFNJVJPLKCPIBV-UHFFFAOYSA-N 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 5
- 235000017557 sodium bicarbonate Nutrition 0.000 description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
- 238000005160 1H NMR spectroscopy Methods 0.000 description 4
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000007112 amidation reaction Methods 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 4
- 239000012230 colorless oil Substances 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 4
- PCAXITAPTVOLGL-UHFFFAOYSA-N 2,3-diaminophenol Chemical compound NC1=CC=CC(O)=C1N PCAXITAPTVOLGL-UHFFFAOYSA-N 0.000 description 3
- HSMJZSLVHGUWCU-UHFFFAOYSA-N COC=1C=C2CCC(=CC2=C(C1OC)OC)CCC Chemical compound COC=1C=C2CCC(=CC2=C(C1OC)OC)CCC HSMJZSLVHGUWCU-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- 239000013566 allergen Substances 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- OQNGCCWBHLEQFN-UHFFFAOYSA-N chloroform;hexane Chemical compound ClC(Cl)Cl.CCCCCC OQNGCCWBHLEQFN-UHFFFAOYSA-N 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- DMEGYFMYUHOHGS-UHFFFAOYSA-N cycloheptane Chemical group C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- ZZYXNRREDYWPLN-UHFFFAOYSA-N pyridine-2,3-diamine Chemical compound NC1=CC=CN=C1N ZZYXNRREDYWPLN-UHFFFAOYSA-N 0.000 description 3
- 238000001953 recrystallisation Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000000967 suction filtration Methods 0.000 description 3
- SSJXIUAHEKJCMH-PHDIDXHHSA-N (1r,2r)-cyclohexane-1,2-diamine Chemical compound N[C@@H]1CCCC[C@H]1N SSJXIUAHEKJCMH-PHDIDXHHSA-N 0.000 description 2
- 125000002030 1,2-phenylene group Chemical group [H]C1=C([H])C([*:1])=C([*:2])C([H])=C1[H] 0.000 description 2
- 125000001140 1,4-phenylene group Chemical group [H]C1=C([H])C([*:2])=C([H])C([H])=C1[*:1] 0.000 description 2
- KLIDCXVFHGNTTM-UHFFFAOYSA-N 2,6-dimethoxyphenol Chemical group COC1=CC=CC(OC)=C1O KLIDCXVFHGNTTM-UHFFFAOYSA-N 0.000 description 2
- VTCDZPUMZAZMSB-UHFFFAOYSA-N 3,4,5-trimethoxyphenol Chemical compound COC1=CC(O)=CC(OC)=C1OC VTCDZPUMZAZMSB-UHFFFAOYSA-N 0.000 description 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- XZAHJRZBUWYCBM-UHFFFAOYSA-N [1-(aminomethyl)cyclohexyl]methanamine Chemical compound NCC1(CN)CCCCC1 XZAHJRZBUWYCBM-UHFFFAOYSA-N 0.000 description 2
- ISKQADXMHQSTHK-UHFFFAOYSA-N [4-(aminomethyl)phenyl]methanamine Chemical compound NCC1=CC=C(CN)C=C1 ISKQADXMHQSTHK-UHFFFAOYSA-N 0.000 description 2
- 150000008065 acid anhydrides Chemical class 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 208000030961 allergic reaction Diseases 0.000 description 2
- OYTKINVCDFNREN-UHFFFAOYSA-N amifampridine Chemical compound NC1=CC=NC=C1N OYTKINVCDFNREN-UHFFFAOYSA-N 0.000 description 2
- 229960004012 amifampridine Drugs 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 210000003651 basophil Anatomy 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- QSKWJTXWJJOJFP-UHFFFAOYSA-N chloroform;ethoxyethane Chemical compound ClC(Cl)Cl.CCOCC QSKWJTXWJJOJFP-UHFFFAOYSA-N 0.000 description 2
- SSJXIUAHEKJCMH-UHFFFAOYSA-N cyclohexane-1,2-diamine Chemical compound NC1CCCCC1N SSJXIUAHEKJCMH-UHFFFAOYSA-N 0.000 description 2
- WJTCGQSWYFHTAC-UHFFFAOYSA-N cyclooctane Chemical group C1CCCCCCC1 WJTCGQSWYFHTAC-UHFFFAOYSA-N 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- GCFHZZWXZLABBL-UHFFFAOYSA-N ethanol;hexane Chemical compound CCO.CCCCCC GCFHZZWXZLABBL-UHFFFAOYSA-N 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 239000008098 formaldehyde solution Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 125000004836 hexamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 2
- 210000003630 histaminocyte Anatomy 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 2
- 229940095102 methyl benzoate Drugs 0.000 description 2
- 125000003506 n-propoxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 125000006633 tert-butoxycarbonylamino group Chemical group 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- CHDNWIQFMFFJJZ-QTCPXKCSSA-N (3R,4R)-1-methylpyrrolidine-3,4-diamine trihydrochloride Chemical compound Cl.Cl.Cl.CN1C[C@@H](N)[C@H](N)C1 CHDNWIQFMFFJJZ-QTCPXKCSSA-N 0.000 description 1
- FZELAUWRSAKWRF-UHFFFAOYSA-N 1,2,3-trimethoxy-5-phenylbenzene Chemical compound COC1=C(OC)C(OC)=CC(C=2C=CC=CC=2)=C1 FZELAUWRSAKWRF-UHFFFAOYSA-N 0.000 description 1
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
- 125000001989 1,3-phenylene group Chemical group [H]C1=C([H])C([*:1])=C([H])C([*:2])=C1[H] 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- CBCKQZAAMUWICA-UHFFFAOYSA-N 1,4-phenylenediamine Chemical compound NC1=CC=C(N)C=C1 CBCKQZAAMUWICA-UHFFFAOYSA-N 0.000 description 1
- HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 1
- WIGRVUWJNPVKPB-UHFFFAOYSA-N 1-methylpyrrolidin-1-ium;chloride Chemical compound Cl.CN1CCCC1 WIGRVUWJNPVKPB-UHFFFAOYSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- WZFUQSJFWNHZHM-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)N1CC2=C(CC1)NN=N2 WZFUQSJFWNHZHM-UHFFFAOYSA-N 0.000 description 1
- GRWKNBPOGBTZMN-UHFFFAOYSA-N 2-benzyl-3-phenylpropane-1,2-diamine Chemical compound C=1C=CC=CC=1CC(N)(CN)CC1=CC=CC=C1 GRWKNBPOGBTZMN-UHFFFAOYSA-N 0.000 description 1
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical class CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 1
- HEMGYNNCNNODNX-UHFFFAOYSA-N 3,4-diaminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1N HEMGYNNCNNODNX-UHFFFAOYSA-N 0.000 description 1
- JHUUPUMBZGWODW-UHFFFAOYSA-N 3,6-dihydro-1,2-dioxine Chemical compound C1OOCC=C1 JHUUPUMBZGWODW-UHFFFAOYSA-N 0.000 description 1
- XUSNPFGLKGCWGN-UHFFFAOYSA-N 3-[4-(3-aminopropyl)piperazin-1-yl]propan-1-amine Chemical compound NCCCN1CCN(CCCN)CC1 XUSNPFGLKGCWGN-UHFFFAOYSA-N 0.000 description 1
- TZZDVPMABRWKIZ-MFTLXVFQSA-N 3-[6-[4-[[1-[4-[(1R,2S)-6-hydroxy-2-phenyl-1,2,3,4-tetrahydronaphthalen-1-yl]phenyl]piperidin-4-yl]methyl]piperazin-1-yl]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound OC=1C=C2CC[C@@H]([C@@H](C2=CC=1)C1=CC=C(C=C1)N1CCC(CC1)CN1CCN(CC1)C=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O)C1=CC=CC=C1 TZZDVPMABRWKIZ-MFTLXVFQSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- UXLBEDYCTWFXIK-UHFFFAOYSA-N 4-fluoro-3-(3,4,5-trimethoxyphenyl)benzoic acid Chemical compound COC1=C(OC)C(OC)=CC(C=2C(=CC=C(C=2)C(O)=O)F)=C1 UXLBEDYCTWFXIK-UHFFFAOYSA-N 0.000 description 1
- YHJVTLSTLZUTQG-UHFFFAOYSA-N 4-methoxy-3-(3,4,5-trimethoxyphenyl)benzoic acid Chemical compound COC1=CC=C(C(O)=O)C=C1C1=CC(OC)=C(OC)C(OC)=C1 YHJVTLSTLZUTQG-UHFFFAOYSA-N 0.000 description 1
- YFFAMQDVOZVJRI-UHFFFAOYSA-N 4-methyl-3-(3,4,5-trimethoxyphenyl)benzoic acid Chemical compound COC1=C(OC)C(OC)=CC(C=2C(=CC=C(C=2)C(O)=O)C)=C1 YFFAMQDVOZVJRI-UHFFFAOYSA-N 0.000 description 1
- MNDCJMKMVWJZFS-UHFFFAOYSA-N 5-(3,4,5-trimethoxyphenyl)pyridine-3-carboxylic acid Chemical compound COC1=C(OC)C(OC)=CC(C=2C=C(C=NC=2)C(O)=O)=C1 MNDCJMKMVWJZFS-UHFFFAOYSA-N 0.000 description 1
- ZWHFYQNKOVGMBG-UHFFFAOYSA-N 5-nitro-2-(3,4,5-trimethoxyphenyl)benzoic acid Chemical compound COC1=C(OC)C(OC)=CC(C=2C(=CC(=CC=2)[N+]([O-])=O)C(O)=O)=C1 ZWHFYQNKOVGMBG-UHFFFAOYSA-N 0.000 description 1
- XVMSFILGAMDHEY-UHFFFAOYSA-N 6-(4-aminophenyl)sulfonylpyridin-3-amine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=N1 XVMSFILGAMDHEY-UHFFFAOYSA-N 0.000 description 1
- CONKBQPVFMXDOV-QHCPKHFHSA-N 6-[(5S)-5-[[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]methyl]-2-oxo-1,3-oxazolidin-3-yl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C[C@H]1CN(C(O1)=O)C1=CC2=C(NC(O2)=O)C=C1 CONKBQPVFMXDOV-QHCPKHFHSA-N 0.000 description 1
- DFGKGUXTPFWHIX-UHFFFAOYSA-N 6-[2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]acetyl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)C1=CC2=C(NC(O2)=O)C=C1 DFGKGUXTPFWHIX-UHFFFAOYSA-N 0.000 description 1
- DEXFNLNNUZKHNO-UHFFFAOYSA-N 6-[3-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperidin-1-yl]-3-oxopropyl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1CCN(CC1)C(CCC1=CC2=C(NC(O2)=O)C=C1)=O DEXFNLNNUZKHNO-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- NRLQBVLOUUPAMI-UHFFFAOYSA-N 8-[3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxybenzoyl]-1-oxa-3,8-diazaspiro[4.5]decan-2-one Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C(=O)N2CCC3(CNC(O3)=O)CC2)C=CC=1 NRLQBVLOUUPAMI-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 102000001381 Arachidonate 5-Lipoxygenase Human genes 0.000 description 1
- 108010093579 Arachidonate 5-lipoxygenase Proteins 0.000 description 1
- 208000012657 Atopic disease Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 229910014033 C-OH Inorganic materials 0.000 description 1
- MTUOLDOWSWYKBG-UHFFFAOYSA-N CCCCCCCCCCCCCCCCOP(O)(O)=O.[C-]#N Chemical compound CCCCCCCCCCCCCCCCOP(O)(O)=O.[C-]#N MTUOLDOWSWYKBG-UHFFFAOYSA-N 0.000 description 1
- KNLMXTDNJUBHJN-UHFFFAOYSA-N COC=1C=C2C=CC(=CC2=C(C1OC)OC)CCC Chemical compound COC=1C=C2C=CC(=CC2=C(C1OC)OC)CCC KNLMXTDNJUBHJN-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 1
- 229910014570 C—OH Inorganic materials 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
- CAIWXFHENZXLQA-YFJLMHTMSA-N FC(C(=O)O)(F)F.FC(C(=O)O)(F)F.FC(C(=O)O)(F)F.CN1C[C@H]([C@@H](C1)CN)CN Chemical compound FC(C(=O)O)(F)F.FC(C(=O)O)(F)F.FC(C(=O)O)(F)F.CN1C[C@H]([C@@H](C1)CN)CN CAIWXFHENZXLQA-YFJLMHTMSA-N 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 101100232925 Mus musculus Il4 gene Proteins 0.000 description 1
- NEAPKZHDYMQZCB-UHFFFAOYSA-N N-[2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]ethyl]-2-oxo-3H-1,3-benzoxazole-6-carboxamide Chemical compound C1CN(CCN1CCNC(=O)C2=CC3=C(C=C2)NC(=O)O3)C4=CN=C(N=C4)NC5CC6=CC=CC=C6C5 NEAPKZHDYMQZCB-UHFFFAOYSA-N 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- XNPOFXIBHOVFFH-UHFFFAOYSA-N N-cyclohexyl-N'-(2-(4-morpholinyl)ethyl)carbodiimide Chemical compound C1CCCCC1N=C=NCCN1CCOCC1 XNPOFXIBHOVFFH-UHFFFAOYSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- HVAUUPRFYPCOCA-AREMUKBSSA-O PAF Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP(O)(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-O 0.000 description 1
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Substances CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- JVMQYIPNUGVKKJ-CHWSQXEVSA-N [(3r,4r)-4-(aminomethyl)-1-benzylpyrrolidin-3-yl]methanamine Chemical compound C1[C@@H](CN)[C@H](CN)CN1CC1=CC=CC=C1 JVMQYIPNUGVKKJ-CHWSQXEVSA-N 0.000 description 1
- GKXVJHDEWHKBFH-UHFFFAOYSA-N [2-(aminomethyl)phenyl]methanamine Chemical compound NCC1=CC=CC=C1CN GKXVJHDEWHKBFH-UHFFFAOYSA-N 0.000 description 1
- FDLQZKYLHJJBHD-UHFFFAOYSA-N [3-(aminomethyl)phenyl]methanamine Chemical compound NCC1=CC=CC(CN)=C1 FDLQZKYLHJJBHD-UHFFFAOYSA-N 0.000 description 1
- OXIKYYJDTWKERT-UHFFFAOYSA-N [4-(aminomethyl)cyclohexyl]methanamine Chemical compound NCC1CCC(CN)CC1 OXIKYYJDTWKERT-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 150000007824 aliphatic compounds Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 150000007514 bases Chemical class 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- XILYOLONIFWGMT-UHFFFAOYSA-N benzene;dihydrochloride Chemical compound Cl.Cl.C1=CC=CC=C1 XILYOLONIFWGMT-UHFFFAOYSA-N 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- HXUAVKFUQQQZRL-UHFFFAOYSA-N chloroform formaldehyde Chemical compound C(Cl)(Cl)Cl.C=O HXUAVKFUQQQZRL-UHFFFAOYSA-N 0.000 description 1
- UXTMROKLAAOEQO-UHFFFAOYSA-N chloroform;ethanol Chemical compound CCO.ClC(Cl)Cl UXTMROKLAAOEQO-UHFFFAOYSA-N 0.000 description 1
- CSTBBLHIGMTEAZ-UHFFFAOYSA-N chloroform;ethyl acetate;hexane Chemical compound ClC(Cl)Cl.CCCCCC.CCOC(C)=O CSTBBLHIGMTEAZ-UHFFFAOYSA-N 0.000 description 1
- ONPSRCNNSZSSMH-UHFFFAOYSA-N chloroform;hexane;methanol Chemical compound OC.ClC(Cl)Cl.CCCCCC ONPSRCNNSZSSMH-UHFFFAOYSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 150000001924 cycloalkanes Chemical class 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- YMHQVDAATAEZLO-UHFFFAOYSA-N cyclohexane-1,1-diamine Chemical compound NC1(N)CCCCC1 YMHQVDAATAEZLO-UHFFFAOYSA-N 0.000 description 1
- VKIRRGRTJUUZHS-UHFFFAOYSA-N cyclohexane-1,4-diamine Chemical compound NC1CCC(N)CC1 VKIRRGRTJUUZHS-UHFFFAOYSA-N 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 239000004914 cyclooctane Substances 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- KJOZJSGOIJQCGA-UHFFFAOYSA-N dichloromethane;2,2,2-trifluoroacetic acid Chemical compound ClCCl.OC(=O)C(F)(F)F KJOZJSGOIJQCGA-UHFFFAOYSA-N 0.000 description 1
- NPOMSUOUAZCMBL-UHFFFAOYSA-N dichloromethane;ethoxyethane Chemical compound ClCCl.CCOCC NPOMSUOUAZCMBL-UHFFFAOYSA-N 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000002085 enols Chemical class 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- MDKXBBPLEGPIRI-UHFFFAOYSA-N ethoxyethane;methanol Chemical compound OC.CCOCC MDKXBBPLEGPIRI-UHFFFAOYSA-N 0.000 description 1
- DECIPOUIJURFOJ-UHFFFAOYSA-N ethoxyquin Chemical group N1C(C)(C)C=C(C)C2=CC(OCC)=CC=C21 DECIPOUIJURFOJ-UHFFFAOYSA-N 0.000 description 1
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 1
- OJCSPXHYDFONPU-UHFFFAOYSA-N etoac etoac Chemical compound CCOC(C)=O.CCOC(C)=O OJCSPXHYDFONPU-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000005446 heptyloxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- NAQMVNRVTILPCV-UHFFFAOYSA-N hexane-1,6-diamine Chemical compound NCCCCCCN NAQMVNRVTILPCV-UHFFFAOYSA-N 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003707 hexyloxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- SXZCBVCQHOJXDR-ILKKLZGPSA-N hydron;methyl (2s)-2,6-diaminohexanoate;dichloride Chemical compound Cl.Cl.COC(=O)[C@@H](N)CCCCN SXZCBVCQHOJXDR-ILKKLZGPSA-N 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- BLJHLOLVEXWHFS-UHFFFAOYSA-N methyl 2,3-diaminobenzoate Chemical compound COC(=O)C1=CC=CC(N)=C1N BLJHLOLVEXWHFS-UHFFFAOYSA-N 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- KMBPCQSCMCEPMU-UHFFFAOYSA-N n'-(3-aminopropyl)-n'-methylpropane-1,3-diamine Chemical compound NCCCN(C)CCCN KMBPCQSCMCEPMU-UHFFFAOYSA-N 0.000 description 1
- SDEZNODBTRWJQZ-UHFFFAOYSA-N n,n'-dibenzylhexane-1,6-diamine Chemical compound C=1C=CC=CC=1CNCCCCCCNCC1=CC=CC=C1 SDEZNODBTRWJQZ-UHFFFAOYSA-N 0.000 description 1
- SPDNCGVVLVTVOV-UHFFFAOYSA-N n,n'-dibenzylhexane-1,6-diamine;dihydrochloride Chemical compound Cl.Cl.C=1C=CC=CC=1CNCCCCCCNCC1=CC=CC=C1 SPDNCGVVLVTVOV-UHFFFAOYSA-N 0.000 description 1
- MDKQJOKKKZNQDG-UHFFFAOYSA-N n,n'-dimethylhexane-1,6-diamine Chemical compound CNCCCCCCNC MDKQJOKKKZNQDG-UHFFFAOYSA-N 0.000 description 1
- RDORKYWHCCIKAM-UHFFFAOYSA-N n,n'-diphenylhexane-1,6-diamine Chemical compound C=1C=CC=CC=1NCCCCCCNC1=CC=CC=C1 RDORKYWHCCIKAM-UHFFFAOYSA-N 0.000 description 1
- JQMRSZJEVQNIPB-UHFFFAOYSA-N n,n'-diphenylpropane-1,3-diamine Chemical compound C=1C=CC=CC=1NCCCNC1=CC=CC=C1 JQMRSZJEVQNIPB-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004957 naphthylene group Chemical group 0.000 description 1
- 125000004923 naphthylmethyl group Chemical group C1(=CC=CC2=CC=CC=C12)C* 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000005447 octyloxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- MUMZUERVLWJKNR-UHFFFAOYSA-N oxoplatinum Chemical compound [Pt]=O MUMZUERVLWJKNR-UHFFFAOYSA-N 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 125000004817 pentamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- 125000004115 pentoxy group Chemical group [*]OC([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 150000003053 piperidines Chemical class 0.000 description 1
- 229910003446 platinum oxide Inorganic materials 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical group CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 150000003222 pyridines Chemical class 0.000 description 1
- VMPYTOIPVPQDNX-UHFFFAOYSA-N pyrrolidin-1-ylmethanamine Chemical compound NCN1CCCC1 VMPYTOIPVPQDNX-UHFFFAOYSA-N 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- SIXLQVWRTHRLNA-UHFFFAOYSA-N tert-butyl n-(pyrrolidin-1-ylmethyl)carbamate Chemical compound CC(C)(C)OC(=O)NCN1CCCC1 SIXLQVWRTHRLNA-UHFFFAOYSA-N 0.000 description 1
- KXQFULJMRNSJRA-CHWSQXEVSA-N tert-butyl n-[[(3r,4r)-1-methyl-4-[[(2-methylpropan-2-yl)oxycarbonylamino]methyl]pyrrolidin-3-yl]methyl]carbamate Chemical compound CN1C[C@@H](CNC(=O)OC(C)(C)C)[C@H](CNC(=O)OC(C)(C)C)C1 KXQFULJMRNSJRA-CHWSQXEVSA-N 0.000 description 1
- YHETUMCLBDCMHI-RYUDHWBXSA-N tert-butyl n-[[(3s,4s)-4-[[(2-methylpropan-2-yl)oxycarbonylamino]methyl]pyrrolidin-3-yl]methyl]carbamate Chemical compound CC(C)(C)OC(=O)NC[C@@H]1CNC[C@H]1CNC(=O)OC(C)(C)C YHETUMCLBDCMHI-RYUDHWBXSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 235000015961 tonic Nutrition 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 229960000716 tonics Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 108010050327 trypticase-soy broth Proteins 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 230000025102 vascular smooth muscle contraction Effects 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/40—Acylated substituent nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
- C07C235/34—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
- C07C235/36—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
- C07C235/38—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/56—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
- C07C237/34—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to an acyclic carbon atom of a hydrocarbon radical substituted by nitrogen atoms not being part of nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
- C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/14—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
Definitions
- the present invention relates to a novel diamide compound and a medicament containing the same as an active ingredient, which is useful for the prevention and treatment of allergic immune diseases.
- IgE a type of immunoglobulin (Ig) is an allergen-specific molecule produced by IgE-producing cells differentiated from B cells, triggered by the contact of immune cells with allergens in vivo. It is.
- IgE is produced in allergic target organs and binds to mast cells, which are the central effector cells in allergic reactions, or receptors on the surface of basophils (sensitized state).
- allergens enter the body and are stimulated by reacting with specific IgE to produce allergic chemical transfer such as histamine, leukotrienes, prostaglandins, and PAF.
- Substances or damaging enzymes such as trypticase are released, causing an immediate-phase allergic reaction such as increased vascular permeability, smooth muscle contraction, and vasodilation.
- stimulated mast cells also secrete site forces, such as IL-4, that directly activate other immune system cells.
- eosinophils, basophils, etc. infiltrate the tissue, and allergic chemical mediators such as these inflammatory cells and tissue-damaging proteins such as MBP induce a late-phase allergic reaction, Prolong the symptoms and make them more severe.
- IgE is a substance that is fundamentally involved in the development of allergic diseases.
- an object of the present invention is to find a compound having a strong inhibitory action on IgE antibody production, and to provide a medicament comprising the compound as an active ingredient and effective against allergic immune diseases. Disclosure of the invention
- the present inventors have conducted intensive studies and as a result, have found that a novel diamide compound represented by the following general formula (1), a salt thereof or a solvate thereof is an excellent IgE antibody.
- the present invention has been found to have a production inhibitory effect and to be useful as a medicament for preventing various allergic immune diseases and as a medicament.
- A represents a phenyl group, a naphthyl group, a dihydronaphthyl group, an indenyl group, a pyridyl group, an indolyl group, an isoindolyl group, a quinolyl group or an itzquinolyl group which may have a substituent;
- X is a lower alkylene group which may have a substituent; an aliphatic cyclic compound which may have a substituent, an aromatic compound which may have a substituent, or which has a substituent A divalent residue of a good heterocyclic compound; an imino group which may have a substituent; a sulfur atom or an oxygen atom;
- Y represents a single bond or a lower alkylene group
- a CH CH—C CHC— or a divalent residue of benzene, pyridine, pyrimidin or pyrazine which may have a substituent;
- R represents a hydrogen atom, a lower alkyl group, a cycloalkyl group, an aryl group or an aralkyl group.
- X is an ethylene group
- Y is a single bond
- Z is -C ⁇ C-I
- R is a hydrogen atom
- A is a phenyl group, a 4-chlorophenyl group and a 4-chlorophenyl group.
- A is not any of a 3,4-dihydrophenyl group, a 3-hydroxy-14-methoxyphenyl group, a 3-methoxy-4-hydroxyphenyl group and a 3,4-dimethoxyphenyl group. ), A salt thereof, or a solvate thereof.
- the present invention also provides a medicine comprising the above compound as an active ingredient.
- the present invention provides a pharmaceutical composition
- a pharmaceutical composition comprising the above compound and a pharmaceutically acceptable carrier.
- the present invention provides the use of the above compound as a medicament.
- the present invention provides a method for treating allergic monoimmune disease, which comprises administering an effective amount of the above compound.
- the diamide compound of the present invention is represented by the general formula (1), and as a compound similar thereto, J. Med. Chem.
- the 5-phenyl-2,4-penic acid derivative of 3 is described, Only been described as an anti-Mararia agent, there is no description as an antiallergic agent c
- JP 6 0 - analogous compound 2 1 4 7 6 6 No. compound of present invention is also applicable to publication (1), wherein although it is described as a 5-lipoxygenase action inhibitor, there is no description that it has an inhibitory effect on IgE antibody production.
- alkyl in the alkyl group, alkylamino group, dialkylamino group and the like usually includes straight-chain or branched-chain alkyl having 1 to 12 carbon atoms. preferable.
- examples of the lower alkyl group include straight or branched ones having 1 to 8 carbon atoms. Specific examples include a methyl group, an ethyl group, an n-propyl group, an i-propyl group, and an n-propyl group.
- Examples of the “alkoxy” in the alkoxy group, the alkoxycarbonyl group, and the like generally include a straight-chain or branched-chain alkoxy having 1 to 12 carbon atoms, and among them, a lower alkoxy group is preferable.
- examples of the lower alkoxy group include a linear or branched alkoxy group having 1 to 8 carbon atoms, and specific examples thereof include a methoxy group, an ethoxyquin group, an n-propoxy group, an i-propoxy group, and an n-propoxy group.
- Examples of the lower alkylene group include a linear or branched alkylene group having 1 to 8 carbon atoms. Specific examples include a methylene group, an ethylene group, a propylene group, a trimethylene group, a tetramethylene group, a pentamethylene group, and a hexamethylene group. Group, heptamethylene group, octamethylene group and the like.
- aliphatic cyclic compound a saturated cyclic hydrocarbon having 3 to 8 carbon atoms, for example, examples thereof include cycloalkanes such as clopentane, cyclohexane, cycloheptane, and cyclooctane.
- aromatic compound examples include an aromatic compound having 6 to 14 carbon atoms such as benzene and naphthalene.
- heterocyclic compounds pyrrolidine, pyridine, as a piperidine, piperidines Rajin, e 5-7 membered c cycloalkyl groups heterocyclic compounds containing 1 to 3 nitrogen atoms, such as Mopiperajin, cyclopropyl And a cycloalkyl group having 3 to 8 carbon atoms such as a cycloalkyl group, a cyclobutyl group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, and a cyclooctyl group.
- aryl group examples include aromatic groups having 6 to 14 carbon atoms, such as a phenyl group and a naphthyl group.
- alkylthio group examples include an alkylthio group having 1 to 8 carbon atoms.
- halogen atom examples include a fluorine atom, a chlorine atom, a bromine atom and an iodine atom.
- A represents a phenyl group, a naphthyl group, a dihydronaphthyl group, an indenyl group, a pyridyl group, an indolyl group, an isoindolyl group, a quinolyl group or an isoquinolyl group. It may have up to 3 substituents.
- the substituents of these groups include a hydroxyl group, a halogen atom, a lower alkyl group which may be substituted with 1 to 3 halogen atoms, a lower alkoxy group, and 1 or 2 lower alkyl groups. Examples thereof include an amino group and an alkylthio group which may be substituted.
- A is particularly preferably a phenyl group substituted by 1 to 3 members selected from a lower alkyl group and a lower alkoxy group.
- the lower alkylene group represented by X is preferably a linear or branched alkylene group having 1 to 8 carbon atoms, more preferably a straight-chain alkylene group having 5 to 8 carbon atoms, and particularly preferably a hexamethylene group.
- an ethylene group is also preferable. This They may have a substituent such as a halogen atom, a hydroxyl group, a lower alkoxy group, a carboxyl group, a lower alkoxycarbonyl group and the like.
- a lower alkylene group which may be substituted by a carboxyl group or a lower alkoxycarbonyl group is particularly preferred.
- the divalent residue of the aliphatic cyclic compound represented by X is preferably a divalent residue of a cycloalcite having 5 to 8 carbon atoms.
- the divalent residue and to the phenylene group, phenylene group is a naphthylene group, and the like are phenylene group are particularly preferred c where the aromatic compound represented by X, 1, 2 - phenylene Any of a len group, a 1,3-phenylene group and a 1,4-phenylene group may be used, but a 1,2-phenylene group and a 1,4-phenylene group are particularly preferred.
- Preferred examples of the divalent residue of the heterocyclic compound represented by X include divalent residues such as pyridine, pyrrolidine, piperidine, piperazine and homopirazine.
- the divalent residue and the imino group of the aliphatic compound, aromatic compound and complex ring compound represented by X are a halogen atom, a hydroxyl group, a lower group which may be substituted with a primary, secondary or tertiary amino group.
- an alkyl group, a lower alkoxy group, a carboxyl group, a lower alkoxycarbonyl group, an amino group, an alkylamino group, a dialkylamino group, a nitro group, a cyano group, an aralkyl group and the like may be substituted.
- the primary, secondary or tertiary amino group includes an amino group, a lower alkylamino group or a di-lower alkylamino group.
- X may have a divalent residue of an aliphatic cyclic compound which may have a substituent, a divalent residue of an aromatic compound which may have a substituent, or may have a substituent More preferably, it is a divalent residue of a heterocyclic compound.
- Y a linear or branched alkylene group having 1 to 8 carbon atoms is preferable.
- Examples of the group that can be substituted for the divalent residue of benzene, pyridine, pyrimidine or pyrazine represented by Z include a halogen atom, a lower alkyl group, a lower alkoxy group, an amino group, a nitro group and the like.
- R is preferably a hydrogen atom, a lower alkyl group, a cycloalkyl group, a phenyl group, or an aralkyl group, particularly a hydrogen atom, a lower alkyl group, a cycloalkyl group having 5 to 8 carbon atoms, a phenyl group, a benzyl group, or a phenylethyl group. Is preferred.
- X is an ethylene group
- Y is a single bond
- Z is —C ⁇ C-one
- R is a hydrogen atom
- A is a phenyl group, 4 monophenyl phenyl group and 4 It is not any of the methoxyphenyl groups.
- X is a trimethylene group
- Y is a single bond
- R is a hydrogen atom
- A is not a 3,4-dichlorophenyl group.
- X is a tetramethylene group
- Y is a single bond
- R is a hydrogen atom
- A is 3, Neither 4-dihydroxyphenyl group, 3-hydroxy-14-methoxyphenyl group, 3-methoxy-14-hydroxyphenyl group nor 3,4-dimethoxyphenyl group.
- the salt of the diamide compound (1) of the present invention is not particularly limited as long as it is a pharmaceutically acceptable salt.
- the diamide compound (1) When the diamide compound (1) is a basic compound, it may be a hydrochloride, a sulfate, or the like.
- the diamide compound (1) may be in the form of a solvate such as a hydrate.
- the diamide compound (1) can be produced, for example, according to the following reaction formula. 0
- the compound (1) of the present invention can be obtained by an amidation reaction between the carboxylic acid (2) and the diamine (3).
- carboxylic acid (2) and diamine (3) can be prepared by mixing a carboxylic acid (2) and diamine (3) in a solvent in the presence of a condensing agent, And a method of reacting in the presence of a base, and (b) a method of reacting a reactive derivative of carboxylic acid (2) with diamine (3) in a solvent.
- a condensing agent e.g., ethylene glycol, ethylene glycol, ethylene glycol, glycerin, 1, 4-butanediol, 1, 4-butane, 1, 4-butanediol, 1, 4-butanediol, 1, 4-butanediol, 1, 4-butanediol, 1, 4-butanediol, 1, 4-butanediol, 1, 4-butanediol, 1, 4-butanediol, 1, 4-butanediol, 1, 4-butanediol, 1, 4-butanediol, 1, 4-butanedi
- an organic base such as pyridine, triethylamine, diisopropylethylamine, or the like, or an inorganic base such as sodium carbonate or sodium hydrogencarbonate
- an inorganic base such as sodium carbonate or sodium hydrogencarbonate
- the condensing agent include 1,3-dicyclohexylcarbodiimide, 1-cyclohexyl-3-morpholinoethylcarbodiimide, 1- (3-dimethylaminopropyl) -13-ethylcarbodiimide, 1'-force Use of porphyridimidazole, cetyl phosphate cyanide, diphenylphosphoryl azide, bis (2-oxo-3-oxazolidine) phosphinyl chloride, 2-chloro-1--1-methylpyridinium iodide, etc.
- carboxylic acid As reactive derivatives, acid halides such as acid chlorides, acid azides, symmetric acid anhydrides, mixed acid anhydrides with vivalic acid, etc., active esters such as cyanomethyl ester, p-ditrophenyl ester etc. are used. can do.
- the amidation reaction is carried out at a reaction temperature of 0 ° C to 100 ° C for 30 minutes to 30 hours in both (a) method and (b) method, for 30 minutes to 30 hours.
- the process is terminated by reacting (3).
- Conventional methods can be used to isolate and purify the compound (1) from the reaction solution. For example, filtration, extraction, washing, drying, concentration, recrystallization, and isolation by various chromatographic methods, etc. It can be purified.
- the compound (1) thus obtained can be converted into an acid addition salt or a base salt by a usual method.
- It may be a solvate such as a reaction solvent or a recrystallization solvent, particularly a hydrate.
- the diamide compound (1) of the present invention has an excellent inhibitory action on IgE antibody production as shown in Examples described later, it can be used for various allergic immune diseases involving IgE, such as asthma and atopic disease. It can be used as a medicine for the prevention and treatment of various allergic diseases such as dermatitis, allergic rhinitis, inflammatory bowel disease, contact dermatitis and allergic eye disease.
- the diamide compound (1) or a salt thereof of the present invention can be prepared by adding a pharmaceutically acceptable inorganic or organic carrier to a solid, semi-solid, liquid, or other various oral or parenteral drug by a conventional method. Agent.
- Preparations for oral administration include tablets, pills, granules, soft and hard capsules, powders, fine granules, powders, emulsions, syrups, pellets, elixirs, etc. .
- Formulations for parenteral administration include injections, drops, infusions, ointments, Roshi yo down, tonics, sprays, suspensions, oils, emulsions, suppositories, valid c inventive eye drops and the like
- the ingredients can be formulated according to conventional methods, but if necessary, surfactants, excipients, coloring agents, flavoring agents, preservatives, stabilizers, buffers, suspending agents, isotonic agents, etc. Can be used as appropriate.
- the dosage of the diamide compound (1) or its salt varies depending on the type, the type of disease to be treated or prevented, the method of administration, the patient's condition, the patient's age, the patient's gender, the patient's weight, the treatment time, etc. However, it can be administered in an amount of 0.01 to 100 OmgZkg—body weight Z days. Such a dose can be administered once or several times a day, for example, divided into 2 to 6 times.
- N N '—Bis [5- (3,4,5—trimethoxyphenyl) pen (1E, 4E) dienol]-1 N, N'-diphenyl-1,6-diaminohexane Manufacturing of:
- Example 11 N, N'-bis [5- (3,4,5-trimethoxyphenyl) pen] (2E, 4E) -dienoyl] 1,4 synthesized under the nitrogen atmosphere by the operation of Example 11 —A solution of bis (aminomethyl) cyclohexane 10 Orag (0.15 mmo ⁇ ) in anhydrous tetrahydrofuran (1 O) was ice-cooled. To this solution was added a solution of n-butyllithium in hexane (1.6 M) 0.20 ⁇ (0.320 ⁇ ), and the mixture was stirred for 10 minutes. (3.2 mmo).
- N N'-bis [5- (3,4,5-trimethoxyphenyl) pen synthesized by the procedure of Example 30 Penichi (2 ⁇ , 4 ⁇ ) ) —Dienomethyl [1,3,4-diaminomethyl benzoate 153 mg (0.23 mmo_n, crude crystals were obtained, and these crude crystals were recrystallized from ethanol to obtain 14 lmg of the title compound. 94%) as a pale yellow crystalline powder. Melting point: 202-205 ° C.
- N N'-bis [5- (3,4,5-trimethoxyphenyl) pen synthesized by the operation of Example 35 (2E, 4E) — [Dienol] — Methyl 3,5-diaminobenzoate (16 1 mg, 0.24 fraction o) to give crude crystals, which were recrystallized from ethanol-ether to give the title compound (156 mg). (99% yield) as pale yellow crystalline powder.
- trans-1—benzyl-3,4-bis ( ⁇ minomethyl) pyrrolidine under ice-cooling, fumaronitrione 29 1 mg (3.7 occluded ⁇ _ ⁇ ) and N-benzyl-1-N 1.06 g (4.5 mmo) of anhydrous methylene chloride (7. After adding a 1 M trifluoroacetic acid methylene chloride solution (0.37 mmo ⁇ ) to the solution, the ice bath was removed and the mixture was stirred at room temperature for 4 hours.
- reaction mixture was washed with a saturated aqueous solution of sodium hydrogen carbonate and saturated saline, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain 789 mg of an oil containing trans-1,4-benzyl-3,4-dicyanopyrrolidine.
- ( 1) 54.6 mg of platinum oxide was added to a solution of the thus obtained oil (789 mg) in ethanol-chloroform (10: 1, 22), and the mixture was stirred at room temperature under a hydrogen atmosphere for 3 days.
- the catalyst was removed from the reaction mixture by suction filtration, the filtrate was concentrated under reduced pressure, 1.5 g (11 mmof) of potassium carbonate was added to a water-methanol solution of the concentrated residue, and the mixture was stirred and concentrated again under reduced pressure.
- the concentrated residue was purified by alumina column chromatography to give the title compound (403 mg, yield 49%) as a colorless oil.
- the reaction mixture was adjusted to a pH of about 10 by adding a 1N aqueous solution of sodium hydroxide thereto, and then extracted with a well-formed form.
- the organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure, and the resulting crude oil was purified by silica gel column chromatography to obtain 90.1 mg (yield: 60%) of crude crystals of the title compound. .
- Trans-3,4-bis (tert-butoxycarbonylamino) 11-methylpyrrolidine synthesized by the method shown in Reference Example 3 was added to a solution of 10 Omg (0.32 mmo £) of tetrahydrofuran in 4N ethyl acetate. Add the solution, stir at room temperature for 2 hours, and then in a bath at 50 ° C for 30 minutes, and then concentrate the reaction mixture under reduced pressure to obtain an oil containing trans-3,4-diamino 1-methylpyrrolidine trihydrochloride. 8 Omg of the product was obtained. By the same operation as in Example 4, 8 Omg of this oily substance and 1-mg of 5- (3,4,5-trimethoxyphenyl) pen (2E, 4E) -genic acid 184 mg
- Example 52 N, N'-bis [5-nitro-2- (3,4,5-trimethoxyphenyl) benzoyl] benzoyl] ethylenediamine synthesized by the method described in Example 2 20 mg ( To a solution of 0.028 acetic acid in ethyl acetate-ethyl acetate (1: 3,2) was added 10% palladium-carbon 2 Omg, and the mixture was stirred at room temperature under a hydrogen atmosphere for 3 hours. The catalyst was removed from the reaction mixture by suction filtration using celite, and the filtrate was concentrated under reduced pressure.
- the concentrated form solution of the concentrated residue was washed with a saturated aqueous solution of sodium hydrogen carbonate and a saturated saline solution, After drying over anhydrous sodium sulfate and concentration under reduced pressure, 17 mg (quantitative) of crude crystals of the title compound were obtained.
- the crude crystals were recrystallized from methylene chloride-ethyl ether to obtain pale yellow crystalline powder.
- the spleen was excised from a mouse (Balb / C, male, 8 weeks old), cut in a 0.3% BSAZHBSS, cut into single cells using a 200 mesh screen, and further treated with 0.75% ammonium chloride. Hemolysis was carried out with a 17 mM Tris solution, and a spleen cell suspension (1 ⁇ 10 ⁇ /? ⁇ ) was prepared using RPMI 1640 medium / 25 mM HPES / 0.3% BSA.
- the drug was added on the first day of the culture, and after the culture, the IgE amount in the culture supernatant was measured by ELISA to calculate the inhibitory effect of the drug on IgE antibody production.
- the diamide compound (1) of the present invention has an activity of suppressing IgE antibody production, it is useful as a medicament for preventing and treating various immune diseases associated with IgE, such as asthma.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pulmonology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pyridine Compounds (AREA)
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP51817598A JP4382880B2 (ja) | 1996-10-11 | 1997-10-08 | 新規なジアミド化合物及びこれを含有する医薬 |
AU44714/97A AU4471497A (en) | 1996-10-11 | 1997-10-08 | Novel diamide compounds and drugs containing the same |
US09/269,764 US6297283B1 (en) | 1996-10-11 | 1997-10-08 | Diamide compounds and compositions containing the same |
EP97943152A EP0934924B1 (en) | 1996-10-11 | 1997-10-08 | Novel diamide compounds and drugs containing the same |
DE69738907T DE69738907D1 (de) | 1996-10-11 | 1997-10-08 | Neue diamidverbindungen und medikamente die diese enthalten |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP26954796 | 1996-10-11 | ||
JP8/269547 | 1996-10-11 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/269,764 A-371-Of-International US6297283B1 (en) | 1996-10-11 | 1997-10-08 | Diamide compounds and compositions containing the same |
US09/858,592 Division US6576642B2 (en) | 1996-10-11 | 2001-05-17 | Diamide compounds and compositions containing the same |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1998016497A1 true WO1998016497A1 (fr) | 1998-04-23 |
Family
ID=17473905
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1997/003603 WO1998016497A1 (fr) | 1996-10-11 | 1997-10-08 | Nouveaux composes de diamide et medicaments les contenant |
Country Status (7)
Country | Link |
---|---|
US (2) | US6297283B1 (ja) |
EP (1) | EP0934924B1 (ja) |
JP (1) | JP4382880B2 (ja) |
AT (1) | ATE404527T1 (ja) |
AU (1) | AU4471497A (ja) |
DE (1) | DE69738907D1 (ja) |
WO (1) | WO1998016497A1 (ja) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6706703B2 (en) | 2001-06-29 | 2004-03-16 | Kowa Co., Ltd. | Bis(5-aryl-2-pyridyl) derivatives |
JPWO2003002535A1 (ja) * | 2001-06-29 | 2004-10-14 | 興和株式会社 | 六員環式基を有する環状ジアミン化合物 |
US6890940B2 (en) | 2001-06-29 | 2005-05-10 | Kowa Co., Ltd. | Bis(2-aryl-5-pyridyl) derivatives |
JP2014529346A (ja) * | 2011-07-29 | 2014-11-06 | エボニック デグサ ゲーエムベーハーEvonik Degussa GmbH | 低分子量生成物、及びディールス−アルダー反応の際の可逆的又は永久的な低温架橋剤としてのそれらの使用 |
JP2019142873A (ja) * | 2014-10-24 | 2019-08-29 | ランドス バイオファーマ インコーポレイテッド | ランチオニンシンテターゼc様2系治療薬 |
JP2020509079A (ja) * | 2017-01-30 | 2020-03-26 | ケムコム エス アー | 悪臭知覚を低減する化合物およびその使用 |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10106852A1 (de) * | 2001-02-14 | 2002-09-05 | T Luger | Entzündungshemmende Verbindungen |
US6867221B2 (en) * | 2001-08-30 | 2005-03-15 | Kowa Co., Ltd. | Cyclic amine compounds and pharmaceutical composition containing the same |
US7125835B2 (en) * | 2002-10-10 | 2006-10-24 | International Flavors & Fragrances Inc | Encapsulated fragrance chemicals |
EP2894175B1 (en) * | 2010-03-11 | 2018-06-20 | Kuraray Co., Ltd. | Crosslinkable composition, crosslinked product and method for production thereof, multilayered structure, crosslinking agent, and compound and method for preparation thereof |
JP2013065011A (ja) * | 2011-09-09 | 2013-04-11 | Rohm & Haas Electronic Materials Llc | マルチアミド成分を含むフォトレジスト |
MY192489A (en) | 2013-10-14 | 2022-08-23 | Eisai R&D Man Co Ltd | Selectively substituted quinoline compounds |
BR112016008378B1 (pt) | 2013-10-14 | 2022-11-08 | Eisai R&D Management Co., Ltd | Compostos de quinolina seletivamente substituídos ou sal dos mesmos, e composição farmacêutica contendo os ditos compostos |
CN105646611B (zh) | 2016-01-19 | 2019-06-11 | 暨南大学 | 一种二咖啡酰亚精胺衍生物糖苷及其用途 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0348648A (ja) * | 1989-06-23 | 1991-03-01 | Boehringer Mannheim Gmbh | 抗動脈硬化薬としての作用を有する医薬及び新規ジ―t―ブチルヒドロキシフエニル誘導体 |
JPH0352852A (ja) * | 1989-07-19 | 1991-03-07 | Yamanouchi Pharmaceut Co Ltd | フェニレン ジウレア誘導体 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4673684A (en) * | 1984-04-04 | 1987-06-16 | Terumo Corporation | Amide derivatives and 5-lipoxygenase inhibitors containing the same as an active ingredient |
JPH01106818A (ja) | 1987-10-20 | 1989-04-24 | Teijin Ltd | 抗アレルギー剤 |
JP2991897B2 (ja) | 1993-06-30 | 1999-12-20 | ハウス食品株式会社 | ガゼットタイプの食品充填用包装袋 |
JP3265134B2 (ja) | 1994-09-20 | 2002-03-11 | 帝人株式会社 | 含窒素二環性複素環誘導体およびこれを含有する医薬製剤 |
CA2165999A1 (en) * | 1994-12-26 | 1996-06-27 | Takahiro Ogawa | Pharmaceutical composition for topical administration to eye for treating allergic conjunctivitis |
JPH1117863A (ja) * | 1997-06-20 | 1999-01-22 | Canon Inc | 画像形成装置 |
-
1997
- 1997-10-08 WO PCT/JP1997/003603 patent/WO1998016497A1/ja active IP Right Grant
- 1997-10-08 AT AT97943152T patent/ATE404527T1/de not_active IP Right Cessation
- 1997-10-08 AU AU44714/97A patent/AU4471497A/en not_active Abandoned
- 1997-10-08 EP EP97943152A patent/EP0934924B1/en not_active Expired - Lifetime
- 1997-10-08 DE DE69738907T patent/DE69738907D1/de not_active Expired - Lifetime
- 1997-10-08 US US09/269,764 patent/US6297283B1/en not_active Expired - Fee Related
- 1997-10-08 JP JP51817598A patent/JP4382880B2/ja not_active Expired - Lifetime
-
2001
- 2001-05-17 US US09/858,592 patent/US6576642B2/en not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0348648A (ja) * | 1989-06-23 | 1991-03-01 | Boehringer Mannheim Gmbh | 抗動脈硬化薬としての作用を有する医薬及び新規ジ―t―ブチルヒドロキシフエニル誘導体 |
JPH0352852A (ja) * | 1989-07-19 | 1991-03-07 | Yamanouchi Pharmaceut Co Ltd | フェニレン ジウレア誘導体 |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6706703B2 (en) | 2001-06-29 | 2004-03-16 | Kowa Co., Ltd. | Bis(5-aryl-2-pyridyl) derivatives |
JPWO2003002535A1 (ja) * | 2001-06-29 | 2004-10-14 | 興和株式会社 | 六員環式基を有する環状ジアミン化合物 |
US6890940B2 (en) | 2001-06-29 | 2005-05-10 | Kowa Co., Ltd. | Bis(2-aryl-5-pyridyl) derivatives |
US7196101B2 (en) | 2001-06-29 | 2007-03-27 | Kowa Co., Ltd | Bis(5-aryl-2-pyridyl) derivatives |
JP2014529346A (ja) * | 2011-07-29 | 2014-11-06 | エボニック デグサ ゲーエムベーハーEvonik Degussa GmbH | 低分子量生成物、及びディールス−アルダー反応の際の可逆的又は永久的な低温架橋剤としてのそれらの使用 |
US10030105B2 (en) | 2011-07-29 | 2018-07-24 | Evonik Degussa Gmbh | Low molecular weight products and use thereof as reversible or permanent low-temperature crosslinking agent in Diels-Alder reactions |
JP2019142873A (ja) * | 2014-10-24 | 2019-08-29 | ランドス バイオファーマ インコーポレイテッド | ランチオニンシンテターゼc様2系治療薬 |
JP2020509079A (ja) * | 2017-01-30 | 2020-03-26 | ケムコム エス アー | 悪臭知覚を低減する化合物およびその使用 |
US11382848B2 (en) | 2017-01-30 | 2022-07-12 | Chemcom S.A. | Compounds reducing malodour perception and the use thereof |
Also Published As
Publication number | Publication date |
---|---|
EP0934924A1 (en) | 1999-08-11 |
JP4382880B2 (ja) | 2009-12-16 |
US20010039279A1 (en) | 2001-11-08 |
DE69738907D1 (de) | 2008-09-25 |
US6576642B2 (en) | 2003-06-10 |
ATE404527T1 (de) | 2008-08-15 |
AU4471497A (en) | 1998-05-11 |
EP0934924A4 (en) | 2004-08-18 |
EP0934924B1 (en) | 2008-08-13 |
US6297283B1 (en) | 2001-10-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8779151B2 (en) | Orally bioavailable caffeic acid related anticancer drugs | |
WO1998016497A1 (fr) | Nouveaux composes de diamide et medicaments les contenant | |
JP5959501B2 (ja) | 癌ならびに免疫および自己免疫疾患の治療のためのアポトーシス誘導物質 | |
AU2006200864B2 (en) | TNF-alpha production inhibitors | |
JPH11269146A (ja) | 分化誘導剤 | |
RU2069662C1 (ru) | Производные пиразоло [1,5-а] пиридина, или их фармацевтически приемлемые соли и способ их получения | |
JP2013525458A (ja) | 抗癌及び抗増殖活性を示すシクロプロピルジカルボキサミド及び類似体 | |
KR101731602B1 (ko) | 테트라하이드로―이미다조[1,5―a]피라진 유도체 염, 이의 제조방법 및 용도 | |
AU2002364539A1 (en) | Cycloalkyl substituted polyamines for cancer therapy and methods of synthesis therefor | |
AU2016366211A1 (en) | Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists | |
WO2018227065A1 (en) | Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists | |
JP2013507371A (ja) | Gタンパク質共役受容体88の調節因子 | |
US20200048264A1 (en) | Processes for the Preparation of Acalabrutinib and Intermediates Thereof | |
TW587077B (en) | Cyclic amide compound | |
JPH11269140A (ja) | 分化誘導剤 | |
JP4278008B2 (ja) | ジアミド化合物及びこれを含有する医薬 | |
JP4316384B2 (ja) | ヘテロアリール置換アミノシクロヘキサン誘導体 | |
CZ357690A3 (en) | Diamides of n,n'-bis-/alkoxyalkyl/-pyridine-2,4-dicarboxylic acid, process of their preparation, their use and pharmaceutical composition containing thereof | |
EP0623132A1 (en) | Disubstituted polycyclic systems as cognition enhancers | |
JPH02229168A (ja) | ピラゾロン誘導体 | |
WO2016203054A1 (en) | 15-substituted-derivatives of securinine useful in the treatment of cancer | |
US20030022886A1 (en) | Bis (2-aryl-5-pyridyl) derivatives | |
JPH04330060A (ja) | ピリジン−2,4−および−2,5−ジカルボン酸のジ(ニトロキシアルキル)アミド、その製造方法およびその使用 | |
AU698487B2 (en) | Imidazopyridine derivatives | |
NZ795496A (en) | Aminothiazole compounds as c-Kit inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU ID IL IS JP KE KG KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1997943152 Country of ref document: EP Ref document number: 09269764 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1997943152 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
NENP | Non-entry into the national phase |
Ref country code: CA |
|
WWG | Wipo information: grant in national office |
Ref document number: 1997943152 Country of ref document: EP |